Sanders plans to haul insulin executives to testify; Juul agrees to pay $462 million to 6 states and D.C.

Sanders plans to call the chief executives of the country's largest insulin manufacturers to testify before his health committee.  

April 12, 2023 Check out STAT+

Sponsored By

Anna Moneymaker/Getty Images STAT+ | Sanders plans to haul insulin executives to testify in Senate The move will keep the pressure on the companies despite the fact that they plan to lower the list price of older insulin products. By Rachel Cohrs and John Wilkerson Juul agrees to pay $462 million to 6 states and D.C., and to share documents The $462 million settlement will also require the e-cig maker Juul to disclose a number of previously secret documents. By Nicholas Florko STAT+ | Senate hashing out policy details on generics, PBMs, insulin A clearer picture is emerging about what's in — and out — of the Senate's latest health care package, sources tell STAT. By Rachel Cohrs and John Wilkerson Patrick Semansky/AP A controversial hire at Arnold Ventures raises questions about the donor's stance on addiction Arnold Ventures hired the controversial economist Jennifer Doleac to lead its criminal justice portfolio, starting in July. By Sarah Owermohle White House moves to protect some abortion patients' records White House officials said they're consulting with lawmakers, doctors and pharmacies to fight the abortion pill ruling. By Amanda Seitz — Associated Press Opinion: We need a way to tell useful mental health tech from digital snake oil Both the public and developers would benefit from a process that separates useful mental health products from the digital snake oil. By Thomas R. Insel VVIR leadless pacemaker Wireless pacemakers may work for children with slow heart rhythms — but first, doctors need child-sized catheters Until device makers create catheters that fit children's veins, wireless catheters can't be widely used for children with congenital heart block.  By Lizzy Lawrence White House designates xylazine, better known as 'tranq,' as an emerging drug threat The White House will publish a "whole-of-government, nationwide plan" to address xylazine within 90 days, the drug czar said. By Lev Facher

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Daily Recap? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2023, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser